THE INFLUENCE OF RECOMMENDATIONS RELATED TO CARDIOVASCULAR DRUGS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AOTM) IN YEARS 2005-2012 FOR THE REIMBURSEMENT DECISIONS

被引：0

作者：

Ofierska-Sujkowska, G. ^{[1
]}

Jagodzinska-Kalinowska, K. ^{[1
]}

Matusewicz, W. ^{[1
]}

机构：

[1] Agcy Hlth Technol Assessment Poland AOTM, Warsaw, Poland

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 03期

关键词：

D O I：

10.1016/j.jval.2013.03.1540

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A296 / A297

页数：2

共 10 条

[1] LOW EFFICACY OF INNOVATIVE DRUGS AS A KEY FACTOR OF NEGATIVE RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AOTM) IN 2011
Ofierska-Sujkowska, G.
Jagodzinska-Kalinowska, K.
Matusewicz, W.
Pasierski, T.
[J]. VALUE IN HEALTH, 2012, 15 (04) : A26 - A26
[2] THE FOCUS ON CARDIOVASCULAR DRUGS IN WORKS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AOTM) IN YEARS 2005-2011 AS AN EXAMPLE OF A LIGHT TOUCH HTA AGENCY
Ofierska-Sujkowska, G.
Jagodzinska-Kalinowska, K.
Matusewicz, W.
Pasierski, T.
[J]. VALUE IN HEALTH, 2012, 15 (04) : A132 - A132
[3] THE ROLE OF ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IN WORKS AND RECOMMENDATIONS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AOTM) IN YEARS 2005-2011
Ofierska-Sujkowska, G.
Matusewicz, W.
Jagodzinska-Kalinowska, K.
[J]. VALUE IN HEALTH, 2012, 15 (07) : A619 - A619
[4] Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis
Kawalec, Pawel
Malinowski, Krzysztof Piotr
[J]. HEALTH POLICY, 2016, 120 (11) : 1240 - 1248
[5] Do Reimbursement Recommendations by the Canadian Agency for Drugs and Technology in Health Translate Into Coverage Decisions for Orphan Drugs in the Canadian Province of Ontario?
Fontrier, Anna-Maria
Kanavos, Panos
[J]. VALUE IN HEALTH, 2023, 26 (07) : 1011 - 1021
[6] A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) IN POLAND AND THE SCOTTISH MEDICINES CONSORTIUM (SMC)
Kolasa, K.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A250 - A250
[7] THE INFLUENCE OF SAFETY ISSUES ON DECISIONS OF CONSULTATIVE COUNCIL OF THE AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND
Farkowski, M. M.
Baran, J.
Matusewicz, W.
[J]. VALUE IN HEALTH, 2010, 13 (03) : A98 - A98
[8] THE INFLUENCE OF COST-EFFECTIVENESS ISSUES OF THE APPRAISED ORPHAN DRUGS ON RECOMMENDATIONS OF AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AHTAPOL)
Ofierska-Sujkowska, G.
Jagodzinska-Kalinowska, K.
Matusewicz, W.
[J]. VALUE IN HEALTH, 2011, 14 (03) : A21 - A21
[9] APPLICATION OF THRESHOLD VALUE FOR COST-EFFECTIVENESS IN RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND FOR CANCER DRUG TECHNOLOGIES
Zawodnik, A.
Matusewicz, W.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A660 - A660
[10] A COMPARISON OF HTA RECOMMENDATIONS ISSUED BY AGENCY FOR HEALTH TECHNOLOGY ASSESSMENT IN POLAND (AHTAPOL) AND NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE) IN THE UK - CONSIDERATION OF SOCIAL IMPLICATIONS IN HTA
Ceglowska, U.
Kolasa, K.
Hermanowski, T.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A355 - A355

← 1 →